Skip to main content

Table 1 Descriptive demographic and clinical features of the study groups

From: In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases

 

AD-D

AD-MCI

HC

Test value; p

N

22

16

74

–

Sex, N (M/F)

10/12

11/5

31/43

–

Age, mean ± SD

72.18 ± 6.27

71.38 ± 10.53

67.15 ± 13.87

F = 1.84; p = 0.16

MMSE, mean ± SD*

17.92 ± 6.70

26.88 ±1.20

–

T = 4.75; p < 0.001

CDR, mean ± SD*

1.84 ± 0.77

0.50 ± 0.00

–

T = −7.65; p < 0.001

  1. Abbreviations: AD-D Alzheimer’s disease dementia, CDR Clinical Dementia Rating, HC healthy controls, AD-MCI MCI due to Alzheimer’s disease, MMSE Mini-Mental State Examination
  2. *Neither MMSE nor CDR was available in 3 AD-D patients, who were tested by means of the Montreal Cognitive Assessment test (total MoCA score = 11; 12; 19, respectively)
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193